In GC, where tumors often exhibit a highly immunosuppressive TME characterized by low PD‐L1 expression or poor T‐cell infiltration, rendering PD‐1/PD‐L1 inhibitors less effective, the addition of co‐stimulatory receptor agonists holds theoretical appeal. The gene discussed is PDCD1; the disease is gastric cancer.